Small Intestine Neuroendocrine Tumor
Small intestine neuroendocrine tumors are rare tumors that arise from neuroendocrine cells in the small intestine, which can lead to symptoms such as abdominal pain, changes in bowel habits, and flushing.
Midgut Neuroendocrine Tumors: Lu177-Dotatate Treatment Schedule
We are studying whether giving Lu177-Dotatate every 16 weeks can lower serious side effects for patients with advanced midgut neuroendocrine tumors. This trial compares the new schedule to the standard treatment given every 8 weeks.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Are you currently pregnant or breastfeeding?
- Do you have any known allergies to medications like lutetium-177 or somatostatin analogues?
- Have you had any major surgery or systemic therapy in the last 4 weeks?
- Do you have any serious health issues like active hepatitis or HIV?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Hospices Civils De Lyon
Medical Oncology
Bron, France
Centre Francois Baclesse
Medical Oncology
Caen, France
Hopital Beaujon
Medical Oncology
Clichy, France
Sponsor: Grupo Espanol De Tumores Neuroendocrinos
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.